Pricing data from June indicated that outside of some select items where costs continue to grow, inflation is trending back towards the Federal Reserve's inflation goal.
Target-Date Funds With Annuities Are Gaining Ground. Is That Good for Your Retirement Plan? Plus, how income and guaranteed lifetime withdrawal benefits work. Jason Kephart and Ivanna Hampton
Breast cancer treatment in the United States can be extremely expensive, even for those who have health insurance. In 2019, people paid higher out-of-pocket costs for breast cancer care than they did for any other type …
The Justice Department's second attempt to indict former FBI Director James Comey is the latest salvo in what critics call a campaign of retribution on the part of the Trump administration since Donald Trump returned to…
Hundreds of thousands of student loan borrowers have gotten their debts forgiven, or soon will, due to a $23 billion class-action settlement with the U.S. Department of Education.
Democratic senators on Friday demanded information on more than a dozen critical mineral deals with the federal government that potentially benefit the families of President Donald Trump or Commerce Secretary Howard Lut…
Following Microsoft's (MSFT) Q4 earnings and record-setting appreciation ($450 billion in market capitalization gained in a single trading day!), the immediate binary event risk is officially behind us.
Soybeans are trading with Friday morning losses of 1 to 2 ½ cents Futures posted weaker trade late on Thursday, with contracts down fractionally to 4 cents across most contracts. The cmdtyView national average Cash Bean…
Wheat is showing losses on Friday AM trade. The wheat complex posted gains across all three exchanges on Thursday. Chicago SRW futures were 13 to 15 1/4 higher at the close. Open interest was down 5,730 contracts on Thu…
The S&P 500 Index ($SPX) (SPY) on Thursday closed up +1.66%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.19%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +3.36%. September E-mini S&P futures (ESU26)…
Looking at the chart above, SHV's low point in its 52 week range is $109.85 per share, with $110.60 as the 52 week high point — that compares with a last trade of $110.39. Comparing the most recent share price to the 20…
Looking at the chart above, JGRO's low point in its 52 week range is $81.16 per share, with $99.73 as the 52 week high point — that compares with a last trade of $90.87. Comparing the most recent share price to the 200 …
Looking at the chart above, SCHG's low point in its 52 week range is $27.96 per share, with $35.42 as the 52 week high point — that compares with a last trade of $33.72. Comparing the most recent share price to the 200 …
Cotton price action is up another 89 to 125 points across most contracts on Thursday. Futures were 81 to 139 points in the green at Thursday’s close. Crude oil was back down just 50 cents per barrel, with the US dollar …
U.S. lawmakers have requested information from food delivery company DoorDash on its use of Chinese artificial intelligence models, CNBC has learned, as scrutiny around American businesses' use of systems developed by C…
The put contract at the $55.00 strike price has a current bid of $2.50. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $55.00, but will also collect the premium, putti…
Almost four years into the artificial intelligence boom, the world's biggest tech companies are still making grand promises about the future. The problem is, they're burning through their cash in the process.
By Andrea Shalal and Patricia Zengerle WASHINGTON, July 31 (Reuters) – A Russia sanctions bill championed by the late Senator Lindsey Graham faces a tough road in Congress as Democrats and some Republicans raise concern…
We’ve recommended Apple’s iPad as the best tablet for years, and there’s still no real competition. The Apple iPad (11th generation) has enough processing power to run any app or play the latest iPad games, and its high…
Shares of Novo Nordisk fell as much as 10% on Friday after the drugmaker said a late-stage heart drug trial failed to reduce major adverse cardiovascular events, or MACE, compared to a placebo.